RxDoctor Payments Data

Martin Hauptschein, MD

Internal Medicine · Beverly Hills, CANPI 1083733695

Payments from drug & device makers

$6,317in general payments, 2019–2025

Across 96 payments — averaging $65.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$1K
  • Biohaven Pharmaceuticals, Inc.$1K
  • Paratek Pharmaceuticals, Inc.$812
  • AbbVie$572
  • Novo Nordisk$569
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$462
  • plus $1K from 12 others

What the payments were for

  • Consulting fees$3,15950%
  • Travel & lodging$280%
  • Food & beverage$3,11949%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,317 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$19,803
Medicare patients
34
Services billed
204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan34$34,021
EliquisApixaban28$31,814
JardianceEmpagliflozin25$31,052
KerendiaFinerenone21$14,881
OzempicSemaglutide14$13,400
Testosterone11$3,699
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$2,830
Losartan Potassium79$1,697
Rosuvastatin Calcium62$1,300
Metoprolol Succinate47$1,086
Albuterol Sulfate HfaAlbuterol Sulfate33$1,082
Atorvastatin Calcium140$966
SynthroidLevothyroxine Sodium13$819
Pravastatin Sodium46$618
Levothyroxine Sodium62$550

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$99$34,02134 claims
PfizerEliquis$95$31,81428 claims
Boehringer IngelheimJardiance$309$31,05225 claims
BayerKerendia$1,390$14,88121 claims
Novo NordiskOzempic$569$13,40014 claims
AbbVieSynthroid$572$81913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Beverly Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →